Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: J Immunol. 2021 Apr 7;206(9):2122–2134. doi: 10.4049/jimmunol.2100018

Figure 3. Prime-boost RSVNanoVax vaccination induces RSV-specific systemic and local antibody responses.

Figure 3.

Serum was collected from WT mice that received a prime and boost of the indicated nanoparticle formulation, naïve mice, or RSV immune mice that received 4.8 × 106 PFU RSV-A2 56 days or 6 months prior. (A) PreF or (B) postF-directed total IgG, IgG1, or IgG2a was measured by antibody ELISA. (C) F-specific IgA was measured in either whole lung homogenates (preF and postF) or nasal wash fluid (preF only) on day 56 by antibody ELISA. Statistical significance was determined by a 2-way ANOVA with a Dunnett’s post hoc test. Asterisks represent significance between RSVNanoVax d56 and RSV immune d56 and pound symbols represent significance between RSVNanoVax 6 month and RSV immune 6 month. */# p<0.05, **/## p<0.01, ***/### p<0.001. Data represent mean ± SEM of 2 independent experiments (n=8–10).